TLR9 and myelodysplastic syndrome: Importantly, specific therapeutic interruption of the TLR9/ox-mtDNA axis decreases pyroptosis and improves hematopoiesis, demonstrating a novel targetable axis in MDS, a disease with few therapeutic options.